Clinical Trial Detail

NCT ID NCT03259867
Title Combination of TATE and PD-1 Inhibitor in Liver Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Teclison Ltd.
Indications

hepatocellular carcinoma

colorectal cancer

Therapies

Nivolumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.